| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs |
|
Medicine details |
|
| Medicine name | guselkumab (Tremfya®) |
| Formulation | Subcutaneous injection |
| Reference number | 3677 |
| Indication | Alone or in combination with methotrexate (MTX) for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy |
| Company | Janssen-Cilag Ltd |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 17/12/2020 |
| NICE guidance | TA815: Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs |